The Navarra-based company, which currently employs more than 350 workers, is preparing a new strategic plan for the next five years. “Since its foundation, our company has been and will be an important collaborator of the Government of Navarra for the development of the biotechnology sector in the region,” said its CEO, Dámaso Molero.
The management of 3P Biopharmaceuticals (3P) and representatives of its main partner and shareholder, the venture capital fund Keensight Capital, are already preparing a new strategic plan for the next five years. They plan to invest 40 million euros and expand their workforce by a hundred people by 2027.
The company, which specialises in the manufacture of biological medicines (CDMO), has 350 employees and has achieved an average annual increase in sales of “more than 35%” in recent years, according to the company’s management. “Since its foundation, our company has been and will continue to be an important collaborator of the Government of Navarra for the development of the biotechnology sector,” confirmed its CEO, Dámaso Molero.
These statements were made during a visit to the company by the Regional Minister for Economic and Business Development and President of Sodena, Mikel Irujo. Thus, after seeing the company’s situation in situ, both Irujo and the managers of 3P made “a very positive assessment” of the trajectory that the firm has followed since Keensight entered its capital in 2019 with an investment of more than 22 million. Precisely, that contribution will be completed this year with other 5 million.
In view of these figures, Irujo considered that the health sector “is key” for the economy of Navarra, as well as “a priority” included in the Sustainable Strategy for Smart Specialisation (S4). “3P is a clear exponent of traction in the sector and has had the decisive support of the Government of Navarra, through Sodena, since it was set up”, he pointed out.